Results 31 to 40 of about 1,742,061 (410)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I [PDF]

, 2012
Background: Chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphatic leukemia (Ph + ALL) are caused by the t(9;22), which fuses BCR to ABL resulting in deregulated ABL-tyrosine kinase activity.
Badura, Susanne, Khateb, Mamduh, Mahajna, Jamal, Metodieva, Anna, Mian, Afsar Ali, Najajreh, Yousef, Ottmann, Oliver Gerhard, Ruimi, Nili, Ruthardt, Martin   +8 more
core   +1 more source

The clathrin-binding domain of CALM-AF10 alters the phenotype of myeloid neoplasms in mice. [PDF]

, 2012
The PICALM (CALM) gene, whose product is involved in clathrin-mediated endocytosis, has been identified in two recurring chromosomal translocations, involving either MLL or MLLT10 (AF10). We developed a mouse model of CALM-AF10(+) leukemia to examine the
Anastasi, J, Brodsky, FM, Fernald, AA, Le Beau, MM, Stoddart, A, Tennant, TR   +5 more
core   +2 more sources

Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow

Haematologica, 2012
We investigated 15,542 patients with suspected BCR-ABL1- negative myeloproliferative or myelodysplastic/myeloproliferative neoplasm (including 359 chronic myelomonocytic leukemia) by a molecular marker set.
Susanne Schnittger, Ulrike Bacher, Christiane Eder, Frank Dicker, Tamara Alpermann, Vera Grossmann, Alexander Kohlmann, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach   +9 more
doaj   +1 more source

Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies

Haematologica, 2013
We conducted a phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with relapsed, refractory myeloid leukemias.
Gautam Borthakur, Michael G. Rosenblum, Moshe Talpaz, Naval Daver, Farhad Ravandi, Stefan Faderl, Emil J. Freireich, Tapan Kadia, Guillermo Garcia-Manero, Hagop Kantarjian, Jorge E. Cortes   +10 more
doaj   +1 more source

Insights into PI3K/AKT signaling in B cell development and chronic lymphocytic leukemia

FEBS Letters, EarlyView.
This Review explores how the phosphoinositide 3‐kinase and protein kinase B pathway shapes B cell development and drives chronic lymphocytic leukemia, a common blood cancer. It examines how signaling levels affect disease progression, addresses treatment challenges, and introduces novel experimental strategies to improve therapies and patient outcomes.
Maike Buchner
wiley   +1 more source

Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases

Haematologica, 2012
We analyzed 636 patients with diverse myeloproliferative neoplasms or myelodysplastic/myeloproliferative neoplasms for mutations of the Casitas B-cell lymphoma gene (CBLmut) in exons 8 and 9 and performed correlations to other genetic alterations. CBLmut
Susanne Schnittger, Ulrike Bacher, Tamara Alpermann, Andreas Reiter, Madlen Ulke, Frank Dicker, Christiane Eder, Alexander Kohlmann, Vera Grossmann, Andreas Kowarsch, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach   +12 more
doaj   +1 more source

Acute myeloid leukemia: current progress and future directions

Blood Cancer Journal, 2021
Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML.
Hagop Kantarjian, Tapan Kadia, Courtney DiNardo, Naval Daver, Gautam Borthakur, Elias Jabbour, Guillermo Garcia-Manero, Marina Konopleva, Farhad Ravandi   +8 more
doaj   +1 more source

Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring

American journal of hematology/oncology, 2020
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly diagnosed cases of leukemia in adults.
E. Jabbour, H. Kantarjian
semanticscholar   +1 more source

The cytoskeletal control of B cell receptor and integrin signaling in normal B cells and chronic lymphocytic leukemia

FEBS Letters, EarlyView.
In lymphoid organs, antigen recognition and B cell receptor signaling rely on integrins and the cytoskeleton. Integrins act as mechanoreceptors, couple B cell receptor activation to cytoskeletal remodeling, and support immune synapse formation as well as antigen extraction.
Abhishek Pethe, Tanja Nicole Hartmann
wiley   +1 more source

B cell mechanobiology in health and disease: emerging techniques and insights into therapeutic responses

FEBS Letters, EarlyView.
B cells sense external mechanical forces and convert them into biochemical signals through mechanotransduction. Understanding how malignant B cells respond to physical stimuli represents a groundbreaking area of research. This review examines the key mechano‐related molecules and pathways in B lymphocytes, highlights the most relevant techniques to ...
Marta Sampietro, Marco Cellani, Cristina Scielzo   +2 more
wiley   +1 more source